Skip to main content
. Author manuscript; available in PMC: 2022 Jun 13.
Published in final edited form as: ACS Infect Dis. 2021 Jul 13;7(8):2264–2276. doi: 10.1021/acsinfecdis.0c00826

Figure 2.

Figure 2.

FLFLF binds FPR1 but does not activate FPR1-expressing cells in vitro. (A) HEK293T cells were transformed to express GFP-FPR1 (green) to confirm that FLFLF treatment did not lead to nonspecific activation. Untreated controls, Formylmethionyl-leucyl-phenylalanine (FMLP)-treated positive controls, and FLFLF-treated cells were imaged to validate that the FPR1 construct was functional and internalized (arrows) upon FMLP treatment and that pegylated FLFLF did not lead to FPR1 signaling, as indicated by receptor internalization, before PEG12-FLFLF was tested. DAPI-stained nuclei are indicated in blue. (B) FLFLF PEG12 was tested for its binding affinity for FPR1.